Related Experiment Video
Updated: Aug 14, 2025
06:15
Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
Published on: October 27, 2014
27.5K
Preoperative Intralesional Bevacizumab Injection in Primary Pterygium in Tunisian Patients: A Randomized Controlled
Jihene Sayadi1, Dhouha Gouider1, Meher Henchiri1
1Department A, Hedi Raies Institute of Ophthalmology, Faculty of Medicine of Tunis, University of Tunis El Manar, Tunis, Tunisia.
Journal of Current Ophthalmology
|January 16, 2023
Summary
A single preoperative injection of bevacizumab before pterygium surgery significantly reduced patient discomfort and improved lesion appearance. This adjuvant treatment also led to a higher success rate, with no observed complications, suggesting it may lower pterygium recurrence.
Area of Science:
- Ophthalmology
- Surgical Innovation
- Pharmacological Adjuncts
Background:
- Pterygium is a common ocular condition that can cause discomfort and visual impairment.
- Current surgical treatments aim for excision and reconstruction, but recurrence remains a challenge.
- Adjuvant therapies are being explored to improve surgical outcomes and reduce recurrence rates.
Purpose of the Study:
- To evaluate the efficacy and safety of a single preoperative intralesional bevacizumab injection as an adjuvant to primary pterygium surgery.
- To assess the impact of bevacizumab on patient-reported functional discomfort and lesion characteristics.
- To determine the effect of bevacizumab on pterygium recurrence rates post-surgery.
Main Methods:
- A randomized controlled trial involving 60 patients with primary pterygium.
- Group A received an intralesional bevacizumab injection one month prior to lesion excision and conjunctival autograft.
- Group B (control) underwent surgery alone, with follow-up at 7 days, 1, 3, and 6 months postoperatively.
Main Results:
- Bevacizumab injection significantly decreased preoperative functional discomfort (P=0.048) and improved lesion grade and color intensity (P=0.001).
- The surgical success rate was statistically higher in the bevacizumab group (P=0.047).
- No local or systemic complications were observed; recurrence was associated with color intensity, vascularity, and elastic tissue degeneration.
Conclusions:
- A single preoperative intralesional bevacizumab injection is safe and effective as an adjuvant treatment for primary pterygium.
- Bevacizumab reduces vascularity, potentially lowering the recurrence rate of pterygium.
- This approach offers improved functional and aesthetic outcomes for patients undergoing pterygium surgery.
